Who
John Goll
SVP, Finance & CAO
Company insider
Files Form 4 as: SVP, Finance & CAO, Immunocore Holdings; Chief Accounting Officer, Insmed.
In numbers
- Trades disclosed
- 19
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $546K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 18 Nov 2019
- Last trade
- 18 Feb 2026
- Last filed
- 19 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Feb 2026filed 19 Feb 2026 | IMCR Immunocore HoldingsBiotechnology | SEC FORM 4 Sold | $23K698 at $32.35 | filing |
| 18 Feb 2026filed 19 Feb 2026 | IMCR Immunocore HoldingsBiotechnology | SEC FORM 4 Sold | $23K698 at $32.35 | filing |
| 17 Feb 2026filed 19 Feb 2026 | IMCR Immunocore HoldingsBiotechnology | SEC FORM 4 Code M | —1,351 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,351 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,351 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,411 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,252 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,411 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,252 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | IMCR Immunocore HoldingsBiotechnology | SEC FORM 4 Code M | —1,351 at $0.00 | filing |
| 17 Feb 2025filed 19 Feb 2025 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,802 at $0.00 | filing |
| 17 Feb 2025filed 19 Feb 2025 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,405 at $0.00 | filing |
| 16 Feb 2024filed 21 Feb 2024 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,930 at $0.00 | filing |
| 3 Jan 2020filed 7 Jan 2020 | INSM Insmedoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,260 at $0.00 | filing |
| 3 Jan 2020filed 7 Jan 2020 | INSM InsmedBiotechnology | SEC FORM 4 Code A | —5,263 | filing |
| 3 Jan 2020filed 7 Jan 2020 | INSM InsmedBiotechnology | SEC FORM 4 Code F | $4,940208 at $23.75 | filing |
| 18 Nov 2019filed 20 Nov 2019 | INSM Insmedoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 18 Nov 2019filed 20 Nov 2019 | INSM InsmedBiotechnology | SEC FORM 4 Code M | $315K25,000 at $12.58 | filing |
| 18 Nov 2019filed 20 Nov 2019 | INSM InsmedBiotechnology | SEC FORM 4 Sold | $501K25,000 at $20.04 | filing |
News
Immunocore (NASDAQ:IMCR) Shares Up 8% – Here's WhyIMCR · dailypolitical.com · 20 Oct 2026Head to Head Survey: Immunocore (NASDAQ:IMCR) and Sera Prognostics (NASDAQ:SERA)IMCR · dailypolitical.com · 20 Oct 2026
0 headlines in the last 90 days name John Goll; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.